2020
Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi P, Lee A. Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood 2020, 136: 18-19. DOI: 10.1182/blood-2020-138515.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraQuality-adjusted life yearsIntensive care unitTherapeutic plasma exchangeHERCULES trialCost-effectiveness analysisCaplacizumab treatmentRituximab useTITAN trialHospital lengthTPE sessionsThrombocytopenic purpuraTreatment armsAcquired Thrombotic Thrombocytopenic PurpuraLong-term disease courseThrombotic microangiopathy leadingEnd-organ damagePlatelet count recoveryLong-term followHealth system perspectiveOne-way sensitivity analysesPotential confounding factorsCost-effectiveness ratioLife-threatening diseaseEndotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patients
2018
A Cluster of Cases of Babesia microti Among Neonates Traced to a Single Unit of Donor Blood
Glanternik JR, Baine IL, Rychalsky MR, Tormey CA, Shapiro ED, Baltimore RS. A Cluster of Cases of Babesia microti Among Neonates Traced to a Single Unit of Donor Blood. The Pediatric Infectious Disease Journal 2018, 37: 269-271. PMID: 28945680, DOI: 10.1097/inf.0000000000001803.Peer-Reviewed Original ResearchConceptsNeonatal intensive care unitHigh-grade parasitemiaTransfusion-transmitted babesiosisIntensive care unitCluster of casesBlood transfusionPremature infantsCare unitExchange transfusionDonor bloodInfantsBabesia microtiTransfusionBabesiosisNeonatesParasitemiaAzithromycinCliniciansAtovaquoneSingle unitBlood